Altimmune
AcquiredPublic · Gaithersburg, United States · Founded 1997
- Headquarters
- Gaithersburg, Maryland
- Employees
- 51–200
- Founded
- 1997
- Business Model
- B2B
- Website
- altimmune.com
- Type
- Public
About
Altimmune is a late clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, developing peptide-based therapeutics for serious liver and metabolic diseases. Its lead candidate, pemvidutide, is a dual-action GLP-1/glucagon receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company traces its roots to Vaxin Inc., founded in 1997 to pioneer new-generation vaccine technologies, and rebranded as Altimmune in 2015. As of December 2025, Altimmune employed 57 full-time staff, including numerous employees holding M.D. or Ph.D. degrees.
Summary
Altimmune is a Biotech company based in Gaithersburg, United States, founded in 1997. Investors include Hercules Capital.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2017
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...